As a registered pharmacist and licensed chemical dependency counselor who works at the intersection of trauma and pharmacology, Scott Beach brings a perspective on DID and medication that is rarely represented in the literature: what does the pharmacist actually need to know?
The Core Clinical Reality: No FDA-Approved Medication for DID
There is no medication approved by the FDA for the treatment of dissociative identity disorder. This is not a gap that has been overlooked — it reflects the nature of DID as a structural, developmental disorder rather than a biochemical one. DID is not caused by a neurotransmitter deficit that can be corrected pharmacologically. It develops as a response to severe, repeated early trauma, and it is treated through psychotherapy, particularly phased trauma therapy guided by the ISSTD guidelines.
This matters clinically because the absence of a primary pharmacological target creates real risk: medication is prescribed for the symptoms that are visible, without adequate assessment of the condition that produces them. The result is often a patient with unrecognized DID who is on an evolving medication regimen — antidepressants, mood stabilizers, antipsychotics, anxiolytics — that addresses comorbid symptoms without touching the underlying structure.
What Medication Can and Cannot Do
Medication can be useful adjunctively in DID — not to treat dissociation itself, but to manage specific comorbid presentations that interfere with the person’s ability to engage with therapy:
- Depression: SSRIs and SNRIs are commonly used for depressive symptoms in DID patients. They can improve mood floor and reduce the depth of depressive episodes without affecting the dissociative architecture.
- PTSD-related hyperarousal: Prazosin is used off-label for PTSD-related nightmares and hyperarousal. Some DID patients report benefit. Alpha-1 antagonism reduces noradrenergic hyperarousal during the night.
- Anxiety: Non-benzodiazepine anxiolytics (buspirone, hydroxyzine) and SSRIs are preferable to benzodiazepines in DID. Benzodiazepines carry specific risks in this population (see below).
- Sleep disruption: Low-dose trazodone or mirtazapine is sometimes used for sleep without the cognitive blunting that accompanies heavier sedatives.
Medication does not:
- Reduce switching or alter identity state structure
- Improve dissociative amnesia
- Integrate parts
- Replace trauma-focused psychotherapy
The Benzodiazepine Problem
Benzodiazepines are commonly prescribed to people with DID — often for anxiety, panic, or sleep — without appreciation for the specific risks they carry in this population.
The primary risk is pharmacokinetic: benzodiazepines produce cognitive disinhibition and amnesia through GABAergic potentiation. In a person whose identity architecture already involves structured amnesia and dissociation, benzodiazepines can:
- Deepen inter-state amnesia, making therapeutic work harder
- Facilitate switching by lowering the threshold for identity state changes
- Produce state-dependent memory effects in which what is learned or recalled under the drug is unavailable in the drug-free state
- Create pharmacological dissociation that compounds structural dissociation
This does not mean benzodiazepines are absolutely contraindicated in DID — clinical judgment, severity of symptoms, and the specific clinical context all matter. But the prescription of benzodiazepines to a patient who may have unrecognized DID requires specific consideration that standard prescribing frameworks do not address.
State-Dependent Pharmacokinetics
One of the less-discussed clinical realities in DID is state-dependent pharmacokinetics. In a dissociative system, different identity states may have meaningfully different physiological presentations — different resting heart rates, different pain thresholds, different allergy responses (though the evidence on this is controversial), and different subjective responses to medication.
Clinically, what this means is that the “patient” who reports the effect of a medication may not be the same identity state that actually took the medication — or that the state reporting is the same one that was active during the adverse effect. Medication histories in DID should be taken with awareness that different parts may have different relationships to the same drug, different memory of dosing, and different accounts of efficacy and side effects.
For prescribers, this raises a practical question that standard prescribing frameworks do not address: who in the system are you prescribing to?
Antipsychotics and the Misdiagnosis Problem
As discussed in the differential diagnosis article, DID is frequently misclassified as a schizophrenia-spectrum disorder when internal voices are the presenting symptom. The clinical consequence is antipsychotic prescribing.
Low-dose antipsychotics are sometimes used adjunctively in DID — particularly for hypervigilance, impulsivity, or agitation — but the evidence base is limited. What is clinically important is this: DID-related internal voices do not typically respond to antipsychotic medication the way psychotic hallucinations do. A clinical response of “the voices didn’t go away” should prompt reconsideration of the diagnosis, not automatic dose escalation.
Second-generation antipsychotics (quetiapine, olanzapine, risperidone) carry metabolic risk profiles that compound the health disparities already present in trauma-exposed populations. Prescribing them long-term for a misdiagnosed condition has real harm potential.
Medication and the Prescribing Relationship
Prescribers who work with DID patients often report that the prescribing relationship itself becomes complicated by the dissociative structure. The patient who comes to the appointment may not be the part that has been managing the medication at home. A part may report adherence while another part has been hoarding, refusing, or altering doses. Medication concerns from one part may never be communicated to the prescribing relationship.
A trauma-informed prescribing approach for DID involves:
- Asking directly whether all parts of the system are in agreement about taking the prescribed medication
- Acknowledging that different parts may have different responses and concerns
- Building alliances with the system as a whole, not only with the presenting part
- Collaborating closely with the treating psychotherapist
- Being explicitly non-punitive about adherence variability
When Medication Comes Before Diagnosis
The most common clinical scenario is not a person with a known DID diagnosis receiving thoughtful adjunctive medication. It is a person with unrecognized DID who has been on an evolving pharmacological regimen for years — accumulating medications for comorbidities while the structural condition remains unaddressed.
From a pharmacist’s perspective, a patient who presents with a complex, polypharmacy regimen that has never produced durable symptom resolution — particularly in the context of a trauma history — warrants a re-evaluation that includes dissociation screening. The medication burden itself can become a barrier to the clarity of thought and emotional access that trauma therapy requires.
References
- ISSTD. Guidelines for Treating Dissociative Identity Disorder in Adults, Third Revision. J Trauma Dissociation. 2011;12(2):115-187.
- Brand BL et al. Separating fact from fiction about DID. Harv Rev Psychiatry. 2016;24(4):257-270.
- Loewenstein RJ. Psychopharmacological treatments for dissociative identity disorder. Psychiatric Annals. 2005;35(8):666-673.
- Dell PF, O’Neil JA (eds). Dissociation and the Dissociative Disorders: DSM-V and Beyond. New York: Routledge; 2009.
- Sar V, Ozturk E. Functional dissociation of the self: A sociocognitive approach to dissociation. J Trauma Dissociation. 2007;8(4):69-87.